Publications by authors named "George Haig"

Claim this Profile
E
Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
George M Haig, Deli Wang, Jun Zhao, Ahmed A Othman, Earle E Bain

J Clin Psychiatry· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.
Anastasia Georgiades, Vicki G Davis, Alexandra S Atkins, Anzalee Khan, Trina W Walker, George Haig

Schizophr Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo Response and Practice Effects in Schizophrenia Cognition Trials.
Richard S E Keefe, Vicki G Davis, Philip D Harvey, Alexandra S Atkins, George M Haig

JAMA Psychiatry· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).
Thomas J Hudzik, Ana M Basso, James J Lynch, William M Bracken, Eric G Mohler, George Haig

Pharmacol Biochem Behav· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
George Haig, Deli Wang, Ahmed A Othman, Jun Zhao

Neuropsychopharmacology· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
George M Haig, Earle E Bain, Weining Z Robieson, Jeffrey D Baker, Ahmed A Othman

Am J Psychiatry· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
Richard S E Keefe, George M Haig, Stephen R Marder, Philip D Harvey, Eduardo Dunayevich

Schizophr Bull· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
George M Haig, Yili Pritchett, Andreas Meier, Ahmed A Othman, Coleen Hall

J Alzheimers Dis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.
George M Haig, Earle Bain, Weining Robieson, Ahmed A Othman, Jeffrey Baker

Schizophr Bull· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.
Michael R Hufford, Vicki G Davis, Dana Hilt, Nancy Dgetluck, Yona Geffen, George Haig

Schizophr Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Ahmed A Othman, George Haig, Hana Florian, Charles Locke, Lev Gertsik

Br J Clin Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
Ahmed A Othman, George Haig, Hana Florian, Charles Locke, Jun Zhang

Br J Clin Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid.
Douglas E Feltner, George Haig

J Psychopharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of pregabalin in healthy volunteers.
Howard N Bockbrader, Louis L Radulovic, Edward L Posvar, James C Strand, Christine W Alvey, George M Haig

J Clin Pharmacol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.
Sunny Chapel, Matt M Hutmacher, George Haig, Howard Bockbrader, Rik de Greef

J Clin Pharmacol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
Lesley M Arnold, I Jon Russell, E W Diri, W Rachel Duan, James P Young, George Haig

J Pain· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin.
Leslie J Crofford, Philip J Mease, Susan L Simpson, James P Young, Susan A Martin, George M Haig

Pain· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preliminary effects of pagoclone, a partial GABA(A) agonist, on neuropsychological performance.
Angela F Caveney, Bruno Giordani, George M Haig

Neuropsychiatr Dis Treat· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the abuse potential of pagoclone, a partial GABAA agonist.
Harriet de Wit, Lisa Vicini, George M Haig, Thomas Hunt, Douglas Feltner

J Clin Psychopharmacol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis